Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil's INTO (national trauma and orthopaedics institute) receives international quality assurance accreditation:

This article was originally published in Clinica

Executive Summary

Brazil's national trauma and orthopaedics institute (INTO) is being formally awarded a healthcare quality accreditation from Joint Commission International (JCI). The four-year project, headed by the director of INTO's medical division, Isabela Simoes, entailed 367 quality standards across 11 service areas. Five of these are organisational, and include safety and quality of care, access to intensive care and infection control procedures. Five hospital institutions in Brazil and around 70 worldwide have received an international healthcare quality accreditation, according to INTO. JCI is the office of the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) that performs accreditations outside the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel